Vanda Pharmaceuticals (VNDA) announced that it has acquired U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals, a Johnson & Johnson (JNJ) company. PONVORY is approved by the U.S. FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. PONVORY has a proven safety profile with over 10 years of data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VNDA: